Moderna MRNA is expected to report first-quarter 2025 earnings on May 1, before the opening bell. The company’s earnings beat ...

Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...

In the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) was a top performer, from both a share-price and an ...

and norovirus – respectively in and close to phase 3 testing – along with two therapies for rare diseases methylmalonic acidaemia (MMA) and propionic acidaemia (PA) in phase 1/2 and Moderna's ...

2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present research across multiple infectious disease areas, including COVID-19, influenza, respiratory syncytial virus (RSV), ...

Moderna could have many products on the market and in a variety of areas. Among these, we may find a cytomegalovirus (CMV) vaccine, a personalized cancer vaccine, and a norovirus vaccine.

CAMBRIDGE, MA / ACCESS Newswire / April 7, 2025 / Moderna, Inc. (NASDAQ ... respiratory syncytial virus (RSV), cytomegalovirus (CMV), norovirus, and mpox, at the European Society of Clinical ...